Suinnr
In a phase I trial the toxicity and immunomodulatonr effects of combined treatment with intravenous (i.v.) bispecific monoclonal antibody BIS-I and subcutaneous (s.c.) interleukin 2 (IL-2) was studied in renal cell cancer patients. BIS-1 combines a specificity against CD3 on T lymphocytes with a specificity against a 40 kDa pancarcinoma-associated antigen. EGP-2. Patients received BIS-1 F(ab'):
fragments intravenously at doses of 1. 3 and 5 ;g kg-' body weight during a concomitantly given standard s.c. IL-2 treatment. For each dose. four patients were treated with a 2 h BIS-1 infusion in the second and fourth week of IL-2 therapy. Acute BIS-1 F(ab'):-related toxicity with symptoms of chills, peripheral vasoconstriction and temporary dyspnoea was observed in 2 4 and 5 5 patients at the 3 and 5 jlg kg-' dose level respectively.
The maximum tolerated dose (MTD) of BIS-1 F(ab'), was 5;jg kg-'. Elevated plasma levels of tumour necrosis factor m (TNF-x) and interferon gamma (IFN-y) were detected at the MTD. Flow cytometric analysis showed a dose-dependent binding of BIS-1 F(ab')2 to circulating T lymphocytes. Peripheral blood mononuclear cells (PBMCs) . isolated after treatment with 3 and 5 jg kg-' BIS-1. showed increased specific cytolytic capacity against EGP-2+ tumour cells as tested in an ex ivo performed assay. Maximal killing capacity of the PBMCs. as assessed by adding excess BIS-1 to the assay. was shown to be decreased after BIS-1 infusion at 5 jig kg-' BIS-I F(ab'),. A BIS-1 F(ab'), dose-dependent disappearance of circulating mononuclear cells from the peripheral blood was observed. Within the circulating CD3+CD8 lymphocyte population. LFA-Im-bright and HLA-DR+ T-cell numbers decreased preferentially. It is concluded that i.V.
BIS-I F(ab'
). when combined with s.c. IL-2. has a MTD of 5 jLg kg-'. The treatment endows the T lymphocytes with a specific anti-EGP-2-directed cytotoxic potential.
Interleukin 2 (IL-2)-based immunotherapy has reproducible activity in selected tumours. Renal cell carcinoma (RCC) and melanoma are the malignancies most sensitive to this form of treatment. Objective responses are observed in approximately 20% of patients with RCC. with durable complete remissions occurring in 5% ). Subcutaneous (s.c.) administration of IL-2 has been found to prevent an important part of the toxicity associated with the use of intravenous (i.v.) IL-2 and has been shown to give rise to immunological and anti-tumour effects similar to the i.v. treatment (Sleijfer et al., 1992 : Janssen et al., 1993 . Still. most RCC and melanoma patients and almost all patients with other tumour types do not respond to A new form of immunotherapy in which the specific binding properties of monoclonal antibodies (MAbs) and the killing capacities of cytotoxic effector cells are combined, using bispecific monoclonal antibodies (BsMAbs), has been the subject of several recent studies. BsMAbs used in this treatment concept are composed of the antigen-binding subunits of two different MAbs, giving rise to one antibody with two specificities. BsMAbs which combine specificities against tnggering molecules on cytotoxic effector cells on the one hand and tumour-associated antigens (TAAs) present on target cells on the other are able to redirect the lytic capcity of the effector cell towards a chosen tumour target cell (Bolhuis et al.. 1991) . This concept has been studied in vitro and in vivo for a number of different effector and target cell populations (Kerr et al.. 1990 : Fermni et al.. 1991 : Mezzanzanica et al.. 1991 Segal et al.. 1991; Weiner & Hillstrom, 1991 . Weiner et al.. 1993 (De Leij et al.. 1993) . Antibodies recognising this carcinoma-associated protein have been clustered as SCLC cluster 2 and include CO17-lA and AUA-1 (Herlyn et al.. 1979; Beverly et al., 1988 : De Leij et al.. 1993 . EGP-2 is a membrane-bound 40 kDa glycoprotein which is highly expressed by most carcinomas and is not shed from the cell membrane (Steplewski et al.. 1981) . EGP-2 was also found to be present on all renal cell carcinomas tested by us. although often to a low extent (our own observation). Its expression on normal tissue is restricted to simple epithelia (Varki et al., 1984) . and the antigen is described in a number of clinical studies as a target antigen for MAb-based immunotherapies (Sindelar et al.. 1986; Samonigg et al.. 1992; Kroesen et al.. 1993) . In the present study BIS-1 was combined with s.c. IL-2 treatment. This combination was chosen because target cell lysis by BsMAb-redirected cytotoxic T lymphocytes (CTLs) has been shown to be dependent on preactivation of lymphocytes (Bach et al.. 1989; De Jong et al.. 1990 : Kerr et al.. 1990 ). This implies that effective in vivo targeting of T lymphocytes towards tumour cells by BsMAb should meet the condition of prior immune activation which, in the case of local treatment settings. can be done by ex vivo activation of autologous immune cells (Nitta et al.. 1990 : Weiner & Hillstrom. 1991 . Immune activation in vivo, including T-cell activation. can be attained by s.c. IL-2 therapy (Janssen et al.. 1993 The-Netherlands) in a 5 day weekly cycle for four consecutive weeks as previously described (Sleijfer et al., 1992) . The dose in the first 2 days of the second, third and fourth weeks was reduced to 9 x I06IUday'-followed by 3 days of 18 x 106 IU day-'. Acetaminophen 250-500 mg orally every 4-6 h was given to suppress pyretic reactions. The BIS-1 F(ab'), BsMAb was administered in 100 ml of 0.9% sodium chloride as a 2 h i.v. infusion.
Study protocol
Consecutive cohorts of at least four patients were treated at each dose level in a dose-escalating phase I trial design. Dose levels of 1, 3 and 6 uLg kg-' body weight were planned to be studied. The antibody was administered in the rebound phase of a preceding 5 day s.c. IL-2 cycle when the number of peripheral blood T lymphocytes was high (Janssen et al., 1993) . The first two patients from a particular dose level received the antibody on days 8 and 22 and the following two patients received the antibody on days 8 and 23, in order to study the effects of the antibody both before (day 8 and 22) and during (day 23) a cycle of IL-2 administration. On the day of the antibody infusion, IL-2 was administered 4 h after the end of infusion. The end point of the study was dose-limiting toxicity, defined as toxicity exceeding WHO grade II. The maximum tolerated dose (MTD) was defined as the dose level below that producing dose-limiting toxicity. Immunological parameters, including cytological and functional binding of BIS-l F(ab'),, were monitored before and at the end of the antibody infusion. Quantification of BIS-1 F(ab'), binding to T lymphocytes was done by a flow cytometry-based procedure. Functional binding of BIS-1 F(ab')2 to T lymphocytes was assessed in a standard 5"Crrelease cytotoxicity assay against the target cell lines GLC-IM13 (EGP-2-positive) and GLC-1 (EGP-2-negative).
Toxicity-and response monitormg Before treatment, patients were staged with a full physical examination, determination of WHO performance status, renal, liver, thyroid and haematological function, an ECG and radiological recording of disease extension. During treatment weight and temperature were recorded daily and renal, liver and haematological functions were determined weekly. Thyroid function was determined before and after the whole treatment. Blood samples were taken before the start and at the end of infusion of BIS-1 F(ab'), for analysing BIS-1 F(ab'% binding to T lymphocytes and the cytotoxic capacity of isolated PBMCs in vitro. Vital functions were measured every 30 min during the infusion, every 2 h thereafter and three times daily in the 5 days during which the patients were hospitalised. Toxicity was scored according to standard WHO criteria (Anonymous, 1979) . Dose modifications were planned as follows. In case of toxicity during the BIS-l F(ab')2 infusion exceeding WHO grade II the infusion was abrogated. In the case of weight gain > 5% or an increase in serum creatinine level of more than 100% or a decrease in systolic tension of 25% during the rest of treatment, the IL-2 was discontinued. Treatment could be reinstituted when toxicity had returned to below a grade I level. If IL-2 had to be withheld for more than 5 days the patient went off study. Response was monitored by radiographic techniques as appropriate. Tumour elevations were repeated after 4 weeks of treatment and every 3 months thereafter. A complete response was defined as the disappearance of all evidence of tumour for a minimum of 4 weeks; a partial response was recorded when a 50% or greater decrease in the sum of the products of all diameters of evaluable lesions was reached. Patients with a response less than paritial or an increase of less than 25% for at least 3 months were classified as having stable disease. Flow cYtometric analysis CD3 occupancy by BIS-I F(ab'% was assessed using an indirect immunofluorescence staining procedure in which streptavidin-PE (SAPE) (Becton Dickinson) was used to amplify the BIS-l F(ab')2 detection with biotinylated goat anti-mouse antibodies (Zola et al., 1990) . A 100 jtl aliquot of peripheral EDTA blood or isolated PBMC samples were incubated with phosphate-buffered saline (PBS) or a saturating amount of BIS-1 F(ab%) (21Lg ml-') at 4°C for 30 min.
After one wash with 2 ml of PBS and 50 l GaM-biotin or, as a control for aspecific binding of the conjugate, GaRbiotin (each 40 x diluted in PBS containing 1% pooled human serum) was added to the cell pellet and incubated at 4'C for 30min. After one wash with 2ml of PBS, 10ILI streptavidin-PE was added to the cell pellet and the samples were incubated at 4°C for 30 min. Cells were resuspended in 2 ml of FACS lysing solution (Becton Dickinson), incubated for 10 min at room temperature, washed once with PBS and resuspended in a final volume of 150 iLl PBS for flow cytometnc analysis. The CD3 occupancy was calculated according to the following formula:
in which the sequential incubation steps are given between brackets, MFI is the mean fluorescence intensity, SAPE is streptavidin-PE and t=x represents either t=Oh (before the infusion) or t =2 h (after the infusion).
Changes in leucocyte numbers as induced by the treatment were analysed by a Coulter Leucocounter (Coulter Electronics, Hilaleah, FL, USA). Changes occurring within the CD3/CD8 double-positive cell population as induced by the treatment were analysed by three-colour flow cytometry. CD8-biotin/streptavidin-allophycocyanin (APC) and CD3-PE or CD3-FITC was used to select for CD3/CD8 doublepositive T lymphocytes, and CDI la-FITC and HLA-DR-PE conjugates were used to analyse the presence of LFA-la-and HLA-DR-positive ceUs within the CD3/CD8 cell population.
Staining was performed on 100 ll of peripheral EDTA blood obtained from the patient just prior to (t = 0 h) and directly after (t = 2 h) BIS-1 infusion. In the first step, CD8-biotin was allowed to bind at 4°C for 30 min followed by one wash with 2 ml of PBS. The second step included the addition of either streptavidin-APC, CD3-FITC, HLA-DR-PE or streptavidin-APC, CD3-PE, CD1 
Effector lymphocytes
In order to test the activity of the BIS-1 F(ab')2 preparation, PBMCs isolated from healthy volunteers were activated by incubating the cells for 3 days in complete medium supplemented with 5% (giving about 0.5 gig ml-' IgG end concentration) culture supernatant of the mitogenic anti-CD3 MAb WT-32 (Tax et al., 1983) , followed by washing and incubation for two additional days in complete medium supplemented with 60 IU ml-I IL-2 (EuroCetus, Amsterdam, The Netherlands). To assess functional binding of BIS-1 F(ab'), to T lymphocytes in the clinical study, freshly isolated PBMCs drawn from the patients just before and after the 2 h antibody infusion were used directly in the 5"Cr-release cytotoxicity assay.
Target cell lines GLC-IM13 (EGP-2-positive) and GLC-1 (EGP-2-negative) are small-cell lung cancer (SCLC)-derived cell lines (De Leij et al., 1985 
Results
In vitro effectiveness and characteristics of BIS-J F(ab')2
The purified BIS-1 F(ab')2 fragment preparation used in this study was analysed by SDS-PAGE. No undigested IgG could be detected (data not shown). In agreement with this, the preparation induced no Fc-mediated cytotoxicity of activated cytotoxic T lymphocytes towards the FcR-positive target cell line P815. whereas undigested BIS-I IgG did (Figure 1 ). BIS-1 F(ab')2 proved to be equally as able as undigested BIS-1 IgG of redirecting cytotoxic T lymphocytes towards EGP-2-positive. but not EGP-2-negative, tumour cells. Optimal target cell lysis is induced in both cases at a concentration of 0.1 g ml1' BIS-in which the actual BIS-I F(ab'). concentration was corrected for its lower molecular weight. The degree to which CD3 molecules on T lymphocytes are occupied with BIS-1 at this concentration is 27%. but even at a CD3 occupancy as low as 2% (1 ng ml-') considerable target cell-directed cytotoxicity is induced (Figure 1 ). Phase I stud! From October 1992 until June 1993. 14 patients with advanced RCC who showed no response after 4 weeks of s.c. IL-2 treatment were entered. The characteristics of the patients are listed in Table I . All patients were eligible for evaluation of toxicity. Side-effects arising from the BIS-1 F(ab'). administration are listed in Table II . This dosedependent toxicity could be discriminated from the toxicity associated with IL-2 by its acute and rapidly transient characteristics. At the 1 gg kg-' dose level no toxicity was observed. Toxicity occurred in two out of four patients at the 3 yg kg-' dose level and consisted of chills, peripheral vasoconstriction with rise in diastolic tension, temporary dyspnoea and fever. Symptoms started suddenly in all patients. approximately 100min after the start of infusion, and lasted 15-30min. except for the fever, which started approximately 30 min after the end of the infusion and lasted for 1-2 h. No neurotoxicity was observed after administration of the BIS-I F(ab').. In the first patient at the 6 pg kg-' dose level, severe rigors started 1 h after the start of infusion, and became accompanied by increasing dyspnoea with signs of cyanosis, whereupon the infusion had to be abrogated. Symptoms resolved gradually over the next 4-6 h except for fever. The patient had received a total dose just over 5Jg kg'. On day 22. a dose of 5 ;g kg-' could be administered to the same patient as a 2 h infusion, producing toxicity with chills to a grade I toxicity. No further dose escalation was attempted. A total of five other patients were treated at a 5 ytg kg-' dose level, producing grade I-II tox- 5"Cr-release assay at an E T ratio of 100: Figure  2 summarises the results obtained from patients treated with different doses of BIS-1 F(ab')2. At 1 iLg kg-' BIS-I F(ab')2, the presence of mouse antibodies bound to T lymphocytes was just detectable and the degree to which CD3 molecules were occupied was determined to be 1.5% (s.d. 0.4). At 3 gig kg-' BIS-1 F(ab')2, binding of the BsMAb to T lymphocytes was clearly detectable and CD3 occupancy was 4% (s.d. 0.9), whereas at 5 gLg kg-' BIS-1 F(ab')2 CD3 occupancy was 6% (s.d. 3). Within the dose levels described no differences in CD3 occupancy were observed between the first (day 8) and the second (day 22 or 23) infusion of BIS-I F(ab')2. After PBMC isolation, in order to perform 5'Crrelease assays, the CD3 occupancy by BIS-I F(ab'), was measured again and proved to be reduced from 4% to 2.5% (s.d. 0.6) and from 6% to 3% (s.d. 0.5) for doses of 3 and 5;gg kg-' BIS-I respectively. The CD3 occupancy by BIS-l F(ab')2 was found to decrease in the next hours (not shown). (four patients, n=8) and 5 (six patients, n= 12) jigkg' BIS-1 F(ab) (solid bars). After PBMC isolation, done to perform cytotoxicity assays, the CD3 occupancy of T lymphocytes by BIS-1 F(ab'), was measured again (0). ND, not done.
Functional analysis of BIS-I binding
The ability of in vivo BIS-1 F(ab'}-loaded T lymphocytes to exert specific anti-tumour activity was assessed in an in vitro 5'Cr-release assay. PBMCs isolated from peripheral blood obtained just before (t = 0 h) and directly after (t = 2 h) infusion with BIS-1 F(ab')2 were incubated with 5'Cr-labelled EGP-2-positive and -negative target cells at E/T ratios of 1, 10 and 100. Both at t = 0 h and at t = 2 h, the assay was also performed in the presence of additional BIS-1 F(ab} (0.1 igml-') added to the assay to assess the maximal redirected cytotoxic capacity of the PBMC. Figure 3 shows the results of the EGP-2-redirected cytolytic capacity of these freshly isolated PBMCs at an E/T ratio of 100. PBMCs isolated after infusion of 3 gg kg-' BIS-1 F(ab'} showed significantly higher specific anti-tumour activity than PBMCs isolated before the infusion (P<0.04), indicating that the in vivo bound BIS-1 endowed the T lymphocytes with a functional anti-EGP-2 redirected cytotoxic capacity (see Figure  3a . t =0-and t = 2-). At this dose, maximal redirected cytotoxic capacity, before and after the infusion, as assessed by adding 0.1 g ml-' BIS-I F(ab')2 in vitro to the assay, was approximately the same in all patients tested (see Figure 3a , t = 0 + and t = 2 + ). At 5 g kg-l, however, the maximal redirected cytotoxic capacity after the 2 h infusion was found to be significantly lower (P <0.005) than the maximal redirected cytotoxic capacity before infusion using the same E/T ratio (see Figure 3b, t=0+ and t=2+ ). Using the EGP-2-negative target cell line GLC-1, no cytotoxicity could be measured at any of the assessed doses or time points, indicating that possible LAK activity did not interfere with this assay (data not shown). Treatment-related cvtokine release Since the observed toxicity in the patients treated at the 5 yig kg-' BIS-l F(ab')2 dose level (Table II) might be explained by the release of secondary cytokines. serum levels of TNF-a were assessed in patients treated at 3 and 5 jug kg-' before and at different time points after the infusion ( Figure  4) . Also IFN-y, a cytokine thought to be produced more selectively by activated T cells, was measured in these patients. At 3 ;tg kg-' no elevation of serum TNF-a or IFN-y was found in two patients (nos. 7 and 8) tested. Administration of 5 Lg kg-' body weight BIS-l F(ab')2. however, evoked TNF-a production up to 180 pg ml1', and IFN-y production up to 12 U ml' (patients 9 and 10 tested). Peak levels of TNF-a were found 2 h after the start of the infusion. Peak levels of IFN-y were detected 3 h after the start of the infusion. Both TNF-a and IFN-'y had returned to almost base levels 24 h after the infusion. At 3 and 5 f.g kg-' BIS-1 F(ab')2, however, especially monocyte but also lymphocyte numbers were significantly reduced in the blood (P<0.01 at 3jigkg-' and P<0.005 at 5 Lg kg-'). To analyse this phenomenon more specifically, blood samples obtained from patients 11-14 were stained with CD3, CD8, CDl la (LFA-lac) and anti-HLA-DR before and after infusion with 5 Ag kg-' body weight BIS-I F(ab'),. Changes occurring within the CD3/CD8 double-positive Tlymphocyte population between the blood samples taken before and after the infusion were analysed. Within the CD3/ CD8 double-positive T-cell population, LFA-lx-bright and HLA-DR-positive cells disappeared from the blood to a greater extent (P<0.02 and P<0.01 respectively) as a result of BIS-1 F(ab'% infusion than the LFA-Ict-dim or HLA-DRnegative cells (Table III) . Fugwe 6 Absolute numbers of lymphocytes (x 106 ml-') just before (t = 0 h) and directly after (t = 2 h) infusion with 1 (four patients, n = 8) (a), 3 (four patients, n = 8) (b) (Janssen et al., 1993) , and the latter cells have been shown to migrate to the site of the tumour (Fisher et al., 1989; Pankonin et al., 1990) . However, in RCC patients, who are in fact the best responding patient group, an overall response rate of only approximately 20% to IL-2 therapy is attained (Tibben et al., 1993) . In the present study we also found elevated levels of TNF-x and IFN-y. It remains to be resolved whether the observed toxicity in the higher doses of the present study is still the result of aspecific stimulation of the monocyte/macrophage system or whether it is induced by specific BIS-1 F(ab'}-mediated T-cell activation, or both. The observed toxicity appears to be unrelated to MOC3 1 binding alone, since the EGP-2-recognising antibody MOC31 can be given to patients in a dose of at least 50 mg kg' without any toxic side-effects This last phenomenon appears to be related to the observed rapid reduction in the number of PBMCs in the peripheral blood during the infusion of 5 jig kg-' BIS-F(ab')2. A reduction in PBMCs occurred to a much lesser extent at 3 jig kg-' BIS-1 F(ab')2 (see Figures 5 and 6) .
However, the low number of circulating PBMCs itself cannot explain the reducing killing capacity of the isolated PBMCs since the cytotoxicity assays were performed at a fixed E T ratio. Lymphocyte subset analysis of blood samples taken before and after infusion with 5 gg kg-' BIS-1 F(ab')2 showed, in addition to the general disappearance of PBMCs, a preferential reduction in the percentage of LFA-la-bright and HLA-DR-positive cells within the CD3 CD8 doublepositive lymphocyte population (see Table III ). whereas the percentage of CD3-and CD8-positive cells was not altered by the infusion. The LFA-lIc-bright T-cell population has been described as the main population responsible for cytolytic activity (Morimoto et al.. 1987; Tsubota et al.. 1989) . The importance of LFA-1 for the induction of target cell lysis is also indicated from the observation that ICAM-1-negative target cells are relatively resistant to lysis by BsMAb-redirected cytolytic effector cells (Stotter et al.. 1989; Braakman et al.. 1990; Rivoltini et al.. 1991 : Webb et al.. 1991 . Furthermore. LFA-lac-bright cells have been shown to leave the circulation during acute immune responses (Hviid et al.. 1991 ). As discussed above. extravasation of these cells might have been initiated by the TNF-a produced during the infusion with BIS-1. TNF-a is known to induce up-regulation of endothelial adhesion molecules such as ICAM-1 and Eselectin that are involved in the migration of leucocytes (Nickoloff & Griffiths. 1989; Vogetseder et al., 1989 : Graeves, 1992 : Zimmerman et al., 1992 . Since LFA-la-bright cells have high avidity for both ICAM-1 and -2 (Diamond et al.. 1991) . this might explain the reduction of especially CD3 CD8 LFA-Ix-bright positive T lymphocytes from the circulation. which subsequently explains the observed decreased maximal tagret cell killing in vitro after infusion with 5 tLg kg-' BIS-l F(ab')2. The production of IFN-y in addition to TNF-m. as observed after treatment with 5 tgkg-' BIS-1 F(ab').. can be taken as a further indication of BIS-l-induced T-cell activation.
We observed one partial response in 14 evaluable patients who were unresponsive to initial s.c. IL-2 monotherapy. This is in line with the cytotoxic capacity of the redirected cells observed in *itro. although a late response to IL-2 cannot be excluded. BsMAb-redirected T lvmphocytes, in contrast to genuine HLA-restricted cytotoxic T lymphocytes. are able to exert their lytic capacity only once towards a relevant target cell. Redirected killing capacity can be restored, however, by adding new BsMAbs (Blank-Voorthuis et al.. 1993) . Therefore. to obtain better anti-tumour responses, it might be necessary to give BIS-1 F(ab')2 more than once to the patient.
In conclusion. BIS-1 F(ab')2 can be given to cancer patients with a MTD of 5 pg kg-' as a 2 h infusion. when combined with IL-2. BIS-1 F(ab')> can be detected on peripheral blood T lymphocytes both cytologically and functionally upon i.v. administration of the BsMAb. At 5 ;Lg kg-' BIS-1 F(ab')2 a rapid induction of TNF-x and IFN-y production is observed and a transient leucopenia with a preferential depletion of LFA-la-bright CD8-positive T lymphocytes from the blood is seen. The wide applicability of the EGP-2 antibody warrants further investigations to fully exploit the full potential of this kind of immunotherapy.
